HER2-Targeted Therapies for Metastatic Breast Cancer
Mar 3, 2025 · Trastuzumab deruxtecan is FDA-approved for the treatment of HER2-positive metastatic breast cancers that have progressed on at least one past HER2-targeted therapy for metastatic …
Treating HER2+ Metastatic Breast Cancer - herceptin
Learn about Herceptin® (trastuzumab), a targeted therapy approved for HER2+ metastatic breast cancer treatment. See full safety & Boxed Warnings for more information.
New FDA Approved Drug Combo Offers Hope For Patients
5 days ago · Understanding HER+ Breast Cancer A new FDA-approved treatment for HER2-positive metastatic breast cancer—trastuzumab deruxtecan (Enhertu) in combination with pertuzumab …
FDA Approves Fam-Trastuzumab Deruxtecan-Nxki for Metastatic …
Dec 15, 2025 · The FDA approved trastuzumab deruxtecan plus pertuzumab for first-line HER2-positive metastatic breast cancer after DESTINY-Breast09 showed major PFS gains.
FDA Greenlights Enhertu‑Pertuzumab Combo as First‑Line Therapy for ...
Dec 16, 2025 · The U.S. Food and Drug Administration has granted a breakthrough approval for a combination therapy designed to treat adults with unresectable or metastatic HER2-positive breast …
T-DXd Wins First-Line Indication for HER2+ Breast Cancer
6 days ago · FDA approval moves trastuzumab deruxtecan in combination with pertuzumab into frontline treatment of unresectable or metastatic HER2-positive breast cancer.
FDA Approves Enhertu Plus Perjeta as First-Line Therapy for HER2 ...
Dec 15, 2025 · The FDA has approved Enhertu (fam-trastuzumab deruxtecan-nxki; AstraZeneca and Daiichi Sankyo) plus Perjeta (pertuzumab) for the first-line treatment of adults with unresectable or …
FDA Approves Fam-Trastuzumab Deruxtecan-Nxki With Pertuzumab …
On December 15, 2025, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (Enhertu®) in combination with pertuzumab for the first-line treatment of adults with …
Dana-Farber Research Supports FDA Approval of T-DXd Plus …
Dec 15, 2025 · The U.S. Food and Drug Administration (FDA) has approved trastuzumab deruxtecan (T-DXd) in combination with pertuzumab for first-line treatment of metastatic HER2-positive breast cancer.
Enhertu Plus Pertuzumab: New First-Line Option for Advanced
6 days ago · Enhertu (fam-trastuzumab deruxtecan-nxki) is a type of targeted cancer treatment called an antibody-drug conjugate. The FDA has approved it in combination with another medicine, …